news
Elucidating the pathophysiology of migraines
Researchers show that proteins released from the brain during migraine with aura are transported by CSF to pain-signalling nerves.
List view / Grid view
Migraine
article
SRP-001: redefining pain treatment with a safer, non-opioid analgesic
This Q&A with Dr Hernan A Bazan, CEO and Co-founder of South Rampart Pharma, Inc, discusses the potential merits of novel non-opioid analgesic SPR-001, which is Phase II-ready for acute and neuropathic pain and migraines. Its benefits mean it is poised to disrupt the $87 billion pain management market and…
news
Genetic study identifies promising therapeutic targets for migraines
Researchers have found blood proteins that cause migraines and have a shared link with Alzheimer’s disease that could potentially be prevented by repurposing existing therapeutics.
news
Non-opioid based target identified to potentially treat chronic pain
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
news
Preclinical candidate CGRP antagonist has potential as treatment for migraines
A preclinical candidate calcitonin gene-related peptide (CGRP) antagonist has been nominated for advancement into further preclinical studies as an investigational treatment for migraine.
news
Lilly announces $1m grant for the American Migraine Foundation
10 June 2016 | By Victoria White, Digital Content Producer
The grant will be used to build a registry that will contain clinical data to advance the research and discovery of new treatments for migraine...
news
Vagus nerve stimulation shown to suppress CSDs – a trigger for migraine
12 January 2016 | By Victoria White
Cortical spreading depressions (CSDs) are believed to be responsible for the aura, or visual disturbance, that frequently precedes some migraines, and have been a significant target for pharmaceutical development...
news
Teva and Heptares to develop treatments for migraine
25 November 2015 | By Victoria White
The companies have entered an agreement to discover and develop novel, small-molecule CGRP antagonists for the treatment of migraine...
news
Key US patents granted for GPCR-focused drug discovery platform arising from pioneering research and translational expertise at MRC and MRC Technology
17 December 2014 | By MRC Technology
Structure-based drug discovery platform targets challenging GPCRs linked to human disease...
news
Teva completes acquisition of Labrys
21 July 2014 | By Teva
...opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
news
Teva to acquire Labrys Biologics, Inc.: Novel migraine prophylaxis treatment adds significant new dimension to Teva’s growing pain care franchise
4 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities...